Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7921655 | 0.99 | LMNA (0.48) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7921443 | 0.91 | ATM (0.45) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7442393 | 0.90 | LMNA (0.48) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7444990 | 0.90 | LMNA (0.48) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| Hydrochloric Acid SCHEMBL7921978 | 0.90 | MEN1 (0.44) | LMNAKCNH2MEN1KMT2AATM | |
| SCHEMBL8806780 | 0.90 | LMNA (0.46) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7436136 | 0.89 | LMNA (0.46) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7448375 | 0.89 | LMNA (0.47) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7921250 | 0.89 | CACNA1B (0.42) | LMNAKCNH2CHRM2ADORA3CHRM1 | |
| SCHEMBL7440435 | 0.89 | LMNA (0.52) | LMNAKCNH2CHRM2ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-20130184321-A1 | Model Mouse of Attention Deficit Hyperactivity Disorder, Method for Investigating Effects for Preventing and Alleviating Attention Disorder using the Model Mouse, and Method for Treating Attention Disorder by Suppressing T-Type Calcium Channel | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-18 | — | — | US | claimed |
| EP-2604109-A1 | MODEL MOUSE OF ATTENTION DEFICIT HYPERACTIVITY DISORDER, METHOD FOR INVESTIGATING EFFECTS FOR PREVENTING AND ALLEVIATING ATTENTION DISORDER USING THE MODEL MOUSE, AND METHOD FOR TREATING ATTENTION DISORDER BY SUPPRESSING T-TYPE CALCIUM CHANNEL | Korea Advanced Institute Of Science And Technology (KR) | 2013-06-19 | — | — | EP | claimed |
| WO-2009093774-A1 | METHOD FOR TREATMENT OF ANXIETY DISORDER BY REGULATING T-TYPE CALCIUM CHANNEL | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-07-30 | — | — | WO | claimed |
| US-20090131495-A1 | METHOD FOR THE PREVENTION AND TREATMENT OF ESSENTIAL TREMOR BY REGULATING ALPHA1G T-TYPE CALCIUM CHANNEL OR BY T-TYPE CALCIUM CHANNEL BLOCKERS | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY | 2009-05-21 | — | — | US | claimed |
| EP-0546102-B1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | UPJOHN CO (US) | 1997-10-15 | — | — | EP | claimed |
| WO-1992004338-A1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | THE UPJOHN COMPANY (US) | 1992-03-19 | — | — | WO | claimed |
| JP-11035483-A | — | — | None | — | — | JP | disclosed |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | disclosed |
| EP-3615010-B1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION INC (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-110770221-B | Methods for improving memory and cognition and for treating memory and cognition disorders | 卡维昂公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20060110332-A1 | Agent for medicamentous treatment of acute and chronic pain | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2006-05-25 | — | — | US | disclosed |
| US-6221868-B1 | Remedies/preventives for frequent urination/urinary incontinence and tropone derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2001-04-24 | — | — | US | disclosed |
| JP-H1135483-A | THERAPEUTIC AGENT OR PREVENTING AGENT FOR POLLAKIURIA OR INCONTINENCE OF URINE | NIPPON KAYAKU CO LTD | 1999-02-09 | — | — | JP | disclosed |
| EP-0546102-B1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | UPJOHN CO (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5594144-A | TREATING CEREBROVASCULAR AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0546102-A1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES. | UPJOHN CO (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004338-A1 | TROPOLONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR PREVENTING AND TREATING ISCHEMIC DISEASES | THE UPJOHN COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | LMNA 2620/4885KCNH2 478/4885CHRM2 1143/4885 |
| US-20060110332-A1 | Agent for medicamentous treatment of acute and chronic pain | CACNB3, KCNN3, CACNA1I | LMNA 3257/4885KCNH2 51/4885CHRM2 320/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | LMNA 2525/4885KCNH2 4475/4885CHRM2 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.